Design, synthesis, and bioevaluation of 1h-pyrrolo[3,2-c]pyridine derivatives as colchicine-binding site inhibitors with potent anticancer activities

References

• Steinmetz MO, Prota AE. Microtubule-targeting agents: strategies to hijack the cytoskeleton. Trends Cell Biol. 2018;28(10):776–792.
   PubMed Web of Science ®Google Scholar
• Li Y, Yang GX, Zhang JF, Tang P, Yang CC, Wang G, Chen JC, Liu J, Zhang L, Ouyang L. Discovery, synthesis, and evaluation of highly selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor for the potential treatment of metastatic triple-negative breast cancer. J Med Chem. 2021;64(16):12022–12048.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Arnst KE, Wang Y, Kumar G, Deng S, Yang L, Li GB, Yang J, White SW, Li W, et al. Heterocyclic-fused pyrimidines as novel tubulin polymerization inhibitors targeting the colchicine binding site: structural basis and antitumor efficacy. J Med Chem. 2018;61(4):1704–1718.
   PubMed Web of Science ®Google Scholar
• Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9(10):790–803.
   PubMed Web of Science ®Google Scholar
• Karahalil B, Yardım-Akaydin S, Nacak Baytas S. An overview of microtubule targeting agents for cancer therapy. Arh Hig Rada Toksikol. 2019;70(3):160–172.
   PubMed Web of Science ®Google Scholar
• Yang CPH, Horwitz SB. Taxol(®): the first microtubule stabilizing agent. Int J Mol Sci. 2017;18(8):1733.
   PubMed Web of Science ®Google Scholar
• Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10(3):194–204.
   PubMed Web of Science ®Google Scholar
• Tan L, Wu C, Zhang J, Yu Q, Wang X, Zhang L, Ge M, Wang Z, Ouyang L, Wang Y. Design, synthesis, and biological evaluation of heterocyclic-fused pyrimidine chemotypes guided by X-ray crystal structure with potential antitumor and anti-multidrug resistance efficacy targeting the colchicine binding site. J Med Chem. 2023;66(5):3588–3620.
   PubMed Web of Science ®Google Scholar
• Ravelli RBG, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 2004;428(6979):198–202.
   PubMed Web of Science ®Google Scholar
• Matthew S, Chen QY, Ratnayake R, Fermaintt CS, Lucena-Agell D, Bonato F, Prota AE, Lim ST, Wang X, Díaz JF, et al. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site. Proc Natl Acad Sci U. S. A. 2021;118:e2021847118.
   Google Scholar
• Prota AE, Bargsten K, Northcote PT, Marsh M, Altmann KH, Miller JH, Díaz JF, Steinmetz MO. Structural basis of microtubule stabilization by laulimalide and peloruside A. Angew Chem Int Ed Engl. 2014;53(6):1621–1625.
   PubMed Web of Science ®Google Scholar
• Prota AE, Bargsten K, Diaz JF, Marsh M, Cuevas C, Liniger M, Neuhaus C, Andreu JM, Altmann KH, Steinmetz MO. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proc Natl Acad Sci U S A. 2014;111(38):13817–13821.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang Y, Wang T, Jiang J, Botting CH, Liu H, Chen Q, Yang J, Naismith JH, Zhu X, et al. Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule. Nat Commun. 2016;7(1):12103–12103.
   PubMedGoogle Scholar
• Nogales E, Wolf SG, Downing KH. Structure of the αβ tubulin dimer by electron crystallography. Nature. 1998;391(6663):199–203.
   PubMed Web of Science ®Google Scholar
• Cormier A, Marchand M, Ravelli RBG, Knossow M, Gigant B. Structural insight into the inhibition of tubulin by vinca domain peptide ligands. EMBO Rep. 2008;9(11):1101–1106.
   PubMed Web of Science ®Google Scholar
• Porcù E, Bortolozzi R, Basso G, Viola G. Recent advances in vascular disrupting agents in cancer therapy. Future Med Chem. 2014;6:1485–1498.
   Google Scholar
• Jiménez C, Ellahioui Y, Álvarez R, Aramburu L, Riesco A, González M, Vicente A, Dahdouh A, Ibn Mansour A, Jiménez C, et al. Exploring the size adaptability of the B ring binding zone of the colchicine site of tubulin with para-nitrogen substituted isocombretastatins. Eur J Med Chem. 2015;100:210–222.,
   PubMed Web of Science ®Google Scholar
• Wang J, Miller DD, Li W. Molecular interactions at the colchicine binding site in tubulin: an X-ray crystallography perspective. Drug Discov Today. 2022;27(3):759–776.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li B, Yan R, Xia L, Fan A, Chu Y, Wang L, Wang Z, Jiang A, Zhu H. A class of novel tubulin polymerization inhibitors exert effective antitumor activity via mitotic catastrophe. Eur J Med Chem. 2019;163:896–910.
   PubMed Web of Science ®Google Scholar
• Bai Z, Gao M, Zhang H, Guan Q, Xu J, Li Y, Qi H, Li Z, Zuo D, Zhang W, et al. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Paclitaxel cells by inhibiting P-gp function and inducing mitotic catastrophe. Cancer Lett. 2017;402:81–92.
   PubMed Web of Science ®Google Scholar
• Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendal D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 1989;45(2):209–211.
   PubMedGoogle Scholar
• Kaffy J, Pontikis R, Florent JC, Monneret C. Synthesis and biological evaluation of vinylogous combretastatin A-4 derivatives. Org Biomol Chem. 2005;3(14):2657–2660.
   PubMed Web of Science ®Google Scholar
• Lawrence NJ, Rennison D, Woo M, McGown AT, Hadfield JA. Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg Med Chem Lett. 2001;11(1):51–54.
   PubMed Web of Science ®Google Scholar
• Hamze A, Alami M, Provot O. Developments of isoCombretastatin A-4 derivatives as highly cytotoxic agents. Eur J Med Chem. 2020;190:112110.
   PubMed Web of Science ®Google Scholar
• Yang F, Jian XE, Diao PC, Huo XS, You WW, Zhao PL. Synthesis, and biological evaluation of 3,6-diaryl-[1,2,4]triazolo[4,3-a]pyridine analogues as new potent tubulin polymerization inhibitors. Eur J Med Chem. 2020;204:112625.
   PubMed Web of Science ®Google Scholar
• Li L, Quan D, Chen J, Ding J, Zhao J, Lv L, Chen J. Design, synthesis, and biological evaluation of 1-substituted-2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents. Eur J Med Chem. 2019;184:111732.
   PubMed Web of Science ®Google Scholar
• Madadi NR, Penthala NR, Howk K, Ketkar A, Eoff RL, Borrelli MJ, Crooks PA. Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4. Eur J Med Chem. 2015;103:123–132.
   PubMed Web of Science ®Google Scholar
• Romagnoli R, Oliva P, Salvador MK, Manfredini S, Padroni C, Brancale A, Ferla S, Hamel E, Ronca R, Maccarinelli F, et al. A facile synthesis of diaryl pyrroles led to the discovery of potent colchicine site antimitotic agents. Eur J Med Chem. 2021;214:113229.
   PubMed Web of Science ®Google Scholar
• Zhou P, Chen G, Gao M, Wu J. Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC. Bioorg Med Chem. 2018;26(23–24):6135–6145.
   PubMed Web of Science ®Google Scholar
• El-Gamal MI, Oh CH. Pyrrolo[3,2-c]pyridine derivatives with potential inhibitory effect against FMS kinase: in vitro biological studies. J Enzyme Inhib Med Chem. 2018;33(1):1160–1166.
   PubMed Web of Science ®Google Scholar
• El-Gamal MI, Jung MH, Lee WS, Sim T, Yoo KH, Oh CH. Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines. Eur J Med Chem. 2011;46(8):3218–3226.
   PubMed Web of Science ®Google Scholar
• McCoull W, Bailey A, Barton P, Birch AM, Brown AJ, Butler HS, Boyd S, Butlin RJ, Chappell B, Clarkson P, et al. Indazole-6-phenylcyclopropylcarboxylic acids as selective GPR120 agonists with in vivo efficacy. J Med Chem. 2017;60(7):3187–3197.
   PubMed Web of Science ®Google Scholar
• Liu R, Huang M, Zhang S, Li L, Li M, Sun J, Wu L, Guan Q, Zhang W. Design, synthesis and bioevaluation of 6-aryl-1-(3,4,5-trimethoxyphenyl)-1H-benzo[d]imidazoles as tubulin polymerization inhibitors. Eur J Med Chem. 2021;226:113826.
   PubMed Web of Science ®Google Scholar
• Liu R, Zhang S, Huang M, Guo Z, Li L, Li M, Wu L, Guan Q, Zhang W. Design, synthesis and bioevaluation of 2,7-diaryl-pyrazolo[1,5-a]pyrimidines as tubulin polymerization inhibitors. Bioorg Chem. 2021;115:105220.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang Y, Yang S, Shi L, Xiu Y, Wu Y, Jiang H. 3-aryl-4-(3,4,5-trimethoxyphenyl)pyridines inhibit tubulin polymerisation and act as anticancer agents. J Enzyme Inhib Med Chem. 2024;39(1):2286939.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang Y, Yang S, Xiu Y, Chen W, Wang Y, Xing D. Design, synthesis, and biological evaluation of 4-aryl-9H-carbazoles as tubulin polymerization inhibitors with potent anticancer activities. Arab J Chem. 2023;16(10):105146.
   Web of Science ®Google Scholar
• Deng B, Sun Z, Wang Y, Mai R, Yang Z, Ren Y, Liu J, Huang J, Ma Z, Chen T, et al. Design, synthesis, and bioevaluation of imidazo [1,2-a] pyrazine derivatives as tubulin polymerization inhibitors with potent anticancer activities. Bioorg Med Chem. 2022;76:117098.
   PubMed Web of Science ®Google Scholar